Bruker Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Bruker wird ein jährliches Gewinn- und Umsatzwachstum von 20.8% bzw. 8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 23.5% betragen.

Wichtige Informationen

20.8%

Wachstumsrate der Gewinne

17.6%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	17.6%
Wachstumsrate der Einnahmen	8.0%
Zukünftige Eigenkapitalrendite	23.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In

Aug 22

Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?

Jul 22

Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price

Jun 09

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Apr 11

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

Jan 22

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Jan 08

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Dec 26

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Nov 06

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Oct 23

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Sep 25

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Aug 09

Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?

Jul 27

Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet

Jul 11

If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity

Jun 26

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:BRKR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,959	571	N/A	131	6
12/31/2025	3,721	382	452	616	11
12/31/2024	3,399	256	141	315	12
6/30/2024	3,120	352	168	273	N/A
3/31/2024	3,001	402	181	284	N/A
12/31/2023	2,965	427	243	350	N/A
9/30/2023	2,818	319	206	316	N/A
6/30/2023	2,715	319	201	342	N/A
3/31/2023	2,621	312	149	284	N/A
12/31/2022	2,531	297	145	274	N/A
9/30/2022	2,506	275	119	242	N/A
6/30/2022	2,476	274	114	196	N/A
3/31/2022	2,458	282	176	262	N/A
12/31/2021	2,418	277	190	282	N/A
9/30/2021	2,362	270	254	347	N/A
6/30/2021	2,264	238	312	405	N/A
3/31/2021	2,118	204	304	395	N/A
12/31/2020	1,988	158	235	332	N/A
9/30/2020	1,960	158	169	265	N/A
6/30/2020	1,970	165	140	235	N/A
3/31/2020	2,035	177	141	234	N/A
12/31/2019	2,073	197	140	213	N/A
9/30/2019	2,026	207	144	210	N/A
6/30/2019	1,972	189	124	185	N/A
3/31/2019	1,925	184	159	210	N/A
12/31/2018	1,896	180	191	240	N/A
9/30/2018	1,873	98	170	211	N/A
6/30/2018	1,842	92	179	219	N/A
3/31/2018	1,813	84	N/A	166	N/A
12/31/2017	1,766	79	N/A	154	N/A
9/30/2017	1,706	151	N/A	142	N/A
6/30/2017	1,664	161	N/A	142	N/A
3/31/2017	1,621	152	N/A	177	N/A
12/31/2016	1,611	154	N/A	131	N/A
9/30/2016	1,619	146	N/A	190	N/A
6/30/2016	1,621	111	N/A	208	N/A
3/31/2016	1,646	119	N/A	188	N/A
12/31/2015	1,624	102	N/A	229	N/A
9/30/2015	1,654	66	N/A	149	N/A
6/30/2015	1,677	60	N/A	108	N/A
3/31/2015	1,739	55	N/A	123	N/A
12/31/2014	1,809	57	N/A	114	N/A
9/30/2014	1,853	66	N/A	176	N/A
6/30/2014	1,872	77	N/A	201	N/A
3/31/2014	1,870	83	N/A	182	N/A
12/31/2013	1,839	80	N/A	145	N/A
9/30/2013	1,805	58	N/A	105	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BRKRDas prognostizierte Gewinnwachstum (20.8% pro Jahr) liegt über der Sparquote (2.5%).

Ertrag vs. Markt: BRKRDie Erträge des Unternehmens (20.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.2% pro Jahr).

Hohe Wachstumserträge: BRKREs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: BRKRDie Einnahmen des Unternehmens (8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: BRKRDie Einnahmen des Unternehmens (8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BRKRDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (23.5%)

Bruker Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Bruker Corporation Revises Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 25%

Price target increased by 14% to US$84.55

Bruker Corporation Provides Earnings Guidance for the Fiscal Year 2024

Price target decreased by 11% to US$70.56

Bruker Corporation Revises Revenue Guidance for the Fiscal Year 2023

Recent updates

Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In

Second quarter dividend of US$0.05 announced

Bruker Corporation Announces Quarterly Cash Dividend, Payable on September 16, 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Bruker Corporation to Report Q2, 2024 Results on Aug 06, 2024

Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?

Bruker Corporation Announces Suspension of Injunction Impacting NanoString's CosMx Spatial Molecular Imager Products in Germany

Bruker Corporation Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut Für Molekulare Pharmakologie (FMP) in Berlin

Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price

Bruker Corporation Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics

Bruker: A Confusing Acquisition Spree

Investor sentiment deteriorates as stock falls 15%

New minor risk - Shareholder dilution

Bruker Corporation has completed a Follow-on Equity Offering.

First quarter dividend of US$0.05 announced

Bruker Corporation Announces Quarterly Dividend, Payable on June 17, 2024

Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q), NanoString Technologies Germany GmbH, Nanostring Technologies International, Inc. and NanoString Technologies Netherlands B.V.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bruker Corporation Revises Earnings Guidance for the Year 2024

Now 23% undervalued after recent price drop

Bruker Corporation to Report Q1, 2024 Results on May 02, 2024

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Bruker Corporation: An Aggressive Acquisition Strategy

Bruker Corporation, Annual General Meeting, May 30, 2024

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Corporation Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Chemspeed Technologies AG.

President of Bruker BioSpin Group notifies of intention to sell stock

Insider recently sold US$822k worth of stock

Tecfin S.À R.L. entered into an agreement to acquire Identicare Limited from Tecfin S.À R.L. for €870 million.

Insider notifies of intention to sell stock

Fourth quarter dividend of US$0.05 announced

Consensus EPS estimates increase by 25%

Bruker Corporation Approves Payment of A Quarterly Cash Dividend, Payable on March 15, 2024

Price target increased by 14% to US$84.55

Bruker Corporation Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Bruker Corporation (NasdaqGS:BRKR) acquired Nanophoton Corporation.

Bruker Corporation to Report Q4, 2023 Results on Feb 13, 2024

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire Chemspeed Technologies AG.

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Bruker Corporation (NasdaqGS:BRKR) acquired Tornado Spectral Systems.

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Bruker Corporation Announces Quarterly Dividend, Payable on December 15, 2023

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Price target decreased by 11% to US$70.56

Bruker Corporation Revises Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman exercised options to buy US$3.4m worth of stock.

Bruker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Now 21% undervalued after recent price drop

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Price target decreased by 8.7% to US$80.89

Bruker Corporation Introduces Next-Generation Nanomechanical Test System

Insufficient new directors

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Bruker Introduces Novel 4D-Proteomics™ Timstof® Capabilities

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Upcoming dividend of US$0.05 per share at 0.3% yield

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

Bruker Corporation Approves Payment of Quarterly Cash Dividend in on the Company’s Common Stock, Payable on September 15, 2023

Chairman notifies of intention to sell stock

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chairman exercised options to buy US$4.9m worth of stock.